biostudies-literatureUnknown10(1)Rob LSOTIO a.s.<h4>Background</h4>Most patients with epithelial ovarian cancer (EOC) relapse despite primary debulking surgery and chemotherapy (CT). Autologous dendritic cell immunotherapy (DCVAC) can present tumor antigens to elicit a durable immune response. We hypothesized that adding parallel or sequential DCVAC to CT stimulates antitumor immunity and improves clinical outcomes in patients with EOC. Based on the interim results of sequential DCVAC/OvCa administration and to accommodate the increased interest in maintenance treatment in EOC, the trial was amended by adding Part 2.<h4>Methods</h4>Patients with International Federation of Gynecology and Obstetrics stage III EOC (serous, endometrioid, or mucinous), who underwent cytoreductive surgery up to 3 weeks prior to randomization and were schedulJournal for immunotherapy of cancere003190https://www.ebi.ac.uk/biostudies/studies/S-EPMC8739446biostudies-literatureSafety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.PMC8739446Novotny ZKlat JRob LFucikova JMinar LCibula DChovanec JValha PSpacek JKieszko DSpisek RHrnciarova TMelichar BMallmann PPluta MHraska MBartunkova JBartos PKorolkiewicz RPKnapp PfalseSafety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.<h4>Background</h4>Most patients with epithelial ovarian cancer (EOC) relapse despite primary debulking surgery and chemotherapy (CT). Autologous dendritic cell immunotherapy (DCVAC) can present tumor antigens to elicit a durable immune response. We hypothesized that adding parallel or sequential DCVAC to CT stimulates antitumor immunity and improves clinical outcomes in patients with EOC. Based on the interim results of sequential DCVAC/OvCa administration and to accommodate the increased interest in maintenance treatment in EOC, the trial was amended by adding Part 2.<h4>Methods</h4>Patients with International Federation of Gynecology and Obstetrics stage III EOC (serous, endometrioid, or mucinous), who underwent cytoreductive surgery up to 3 weeks prior to randomization and were schedul2022-01-01T00:00:00Z2022 Jan2026-06-16T03:11:10.388Z2026-06-16T03:06:57.14ZS-EPMC87394463499209110.1136/jitc-2021-003190